Safety in Immunomodulatory Functions of Campath-1H (PC01)
收藏官方服务：
资源简介：
This is a multicenter, open label, single arm trial to evaluate the safety of alemtuzumab after kidney transplantation as part of a multitherapy regimen to prevent kidney graft loss and death and to avoid steroids and chronic use of calcineurin inhibitors in pediatric renal transplant recipients 1 to 20 years of age.
提供机构：
ImmPort创建时间：
2016-11-01
